SUBSTITUTED PYRROLO [2,3-D] PYRIDAZIN-4-ONES AND PYRAZOLO [3,4-D] PYRIDAZIN-4-ONES AS PROTEINKINASE INHIBITORS Russian patent published in 2021 - IPC C07D487/04 A61K31/5025 A61P35/00 

FIELD: pharmaceutical compounds.

SUBSTANCE: invention relates to a compound of Formula (II) or a pharmaceutically acceptable salt thereof, which can find use as inhibitors of Bruton's tyrosine kinase (BTK). In Formula (II), ring Q1 is selected from aryl and heteroaryl, where aryl and heteroaryl are each unsubstituted or substituted with at least one substituent independently selected from R^X, where aryl is phenyl or naphthyl, where heteroaryl is a 5-6 membered aromatic, monocyclic ring containing from 1 to 2 heteroatoms selected from N, with the remaining ring atoms being carbon; ring Q2 is selected from heterocyclyl, where heterocyclyl is a single aliphatic ring with 4-6 ring atoms containing 1 to 2 heteroatoms selected from N; L is selected from -O-, -N(R^A1)C(O)- and -C(O)N(R^A1)-; W is -C(O)-; Y is selected from N and CR⁶; R¹ is hydrogen; each R² is hydrogen; R³ is hydrogen; R⁵ is selected from hydrogen and C_1-10 alkyl; R⁴ is selected from hydrogen, C_1-10 alkyl, heterocyclyl or heterocyclyl-C_1-4 alkyl, where heterocyclyl is unsubstituted or substituted by at least one substituent independently selected from R^X, where heterocyclyl is a single aliphatic ring with 4-5 ring atoms containing 1 heteroatom selected from N; or R³ and R⁴, taken together, form a bond; R⁶ is hydrogen; each R^A1 is hydrogen; each R^X is independently selected from hydrogen, C_1-10 alkyl, halogen, CN and NO₂; n is 0; p is 0. The invention also relates to a pharmaceutical composition for inhibiting the kinase activity of Bruton's tyrosine kinase (BTK), containing an effective amount of the said compound and at least one pharmaceutically acceptable carrier, and to a method of treating, ameliorating or preventing a condition that responds to BTK inhibition, comprising administering to a subject in need of such treatment, an effective amount of the said compound.

EFFECT: invention can be used for treatment of an inflammatory and/or autoimmune condition.

34 cl, 2 tbl, 117 ex

(II)